DNAprint Genomics (DNAG)

[fatboy22]

BUYINS.NET: CSCA, DNAG Have Also Been Removed From Naked Short List Today

Feb 22, 2007 (M2 PRESSWIRE via COMTEX) -- BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE naked short threshold list: Chardan South China Acquisition Corporation (OTCBB: CSCA), DNAPrint Genomics, Inc. (OTCBB: DNAG). For a complete list of companies on the naked short list please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to www.buyins.net.
Chardan South China Acquisition Corporation (OTCBB: CSCA) is a blank check company whose IPO went effective in August 2005. Its mission statement was to acquire an operating business based south of the Yangtze River in the People's Republic of China ("PRC"). In January, 2007 CSCA announced that it had entered into an Agreement in Principal to merge with Head Dragon Holdings, Limited, a Hong Kong Holding company that owns 100% of Liaoning GaoKe Energy Group ("GaoKe"), the largest private Chinese engineering company providing design, construction, installation, and operating expertise for distributed power generation and micro power grids in the PRC. Although GaoKe's principal offices are located north of the Yangtze River in the PRC, CSCA's board and management will obtain shareholder approval for the change in geography in the normal course of closing the transaction. With 7 million shares outstanding and 16 shares declared short as of January 2007, there is no longer a failure to deliver in shares of CSCA.

DNAPrint Genomics, Inc. (OTCBB: DNAG) operates as a developer of genomics-based products and services primarily in biomedical and forensics markets in the United States. Its primary product is PT-401, a Super EPO' (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients. The company's other products under development include PT-501, PT-502, and PT-503 theranostics products for the treatment of attention deficit hyperactivity disorder, drug abuse, and depression, respectively. DNAPrint Genomics' is also developing diagnostic products, including OVANOME for ovarian cancer, STATINOME for the safety of statins, and DIABETES-CD59 for diabetic complications. In addition, it offers DNAWitness product suite, which enables medical examiner's offices, special task forces, sheriffs' departments, and other forensics experts in the law enforcement field to determine genetic heritage from DNA samples obtained from crime scenes; and ANCESTRYbyDNA and EURO-DNA, both are genealogy products that determine genetic heritage. Further, the company provides sequencing and genotyping services to industrial customers. DNAPrint Genomics has strategic alliances with Moffitt Cancer Center, Beth Israel Deaconess Medical Center, and NeoCodex, Inc.; and a collaborative research agreement with Beth Israel. It also has a license agreement with Harvard Medical School, and a research sponsorship agreement with Massachusetts College of Pharmacy and Health Sciences. The company, formerly known as Lexington Energy, Inc., was founded by Tony Frudakis. DNAPrint Genomics was incorporated in 1983 and is headquartered in Sarasota, Florida. With 417 million shares outstanding and 100,102 shares declared short as of January 2007, there is no longer a failure to deliver in shares of DNAG.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 1,200,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.

BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.

BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

CONTACT: Thomas Ronk, CEO, www.buyins.net Tel: [phone] e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].




(C)1994-2007 M2 COMMUNICATIONS LTD

-0-


Search for Dun & Bradstreet reports on this company.